
incyt ido failur neg pure
newlink downgrad hold
buy hold
today announc neg result phase
epacadostat keytruda melanoma believ result signific
neg read newlink ido agent indoximod remov
melanoma model newlink reduc likelihood success
pancreat cancer differ mechan action differ ido combo
help us keep pancreat model drive potenti bull case
scenario downgrad nlnk share hold buy lower pt
buy lawson neg phase result signific
neg read newlink newlink indoximod
differ mechan action epacadostat act ido pathway
produc similar data melanoma date believ today
neg readout see note impli
indoximod like success melanoma also
lower probabl success indoximod chemo pancreat cancer
model chang reduc probabl adjust peak sale
estim consequ price target chang
varianc tabl detail
catalyst nlnk indoximod chemo pancreat cancer data
possibl final indoximod melanoma phase
data like indoximod pediatr brain cancer data
valuat dcf/npv valuat use probabl adjust peak sale
discount rate probabl success yield
pt indoximod cash/technolog
pancreat cancer upsid risk includ ido success pancreat cancer
tr target
data catalyst nlnk next month highlight
page
candidatetimingmilestonesettingindoximod phase indoximod gemcitabin nab-paclitaxel datametastat pancreat indoximod imfinzi soc phase studypancreat phase data pediatr brain cancerpediatr brain phase indoxmiod volunt sad pk data new indoximod salt enrol phase studyadvanc melanoma newlink genet corpor
bull bear case
page
page
 cogs- interest- adjust sale success weight weight indoximod pancreat cancer indoximod solid tumor- technolog newlink genet corpor
page
page
newlink genet clinic stage biopharmaceut compani focus use small molecul
immunotherapi treat cancer newlink genet found june headquart
ame iowa
view newlink genet pure-play immuno-oncolog compani differenti
immmuno-oncolog checkpoint inhibitor indoximod use target multipl
cancer rate stock hold
valuat risk
dcf/npv valuat use probabl adjust peak sale discount rate
probabl success yield pt indoximod
cash/technolog bull/bear case model yield pt downsid risk rate price
target includ ido failur pancreat cancer upsid risk rate price target includ ido
success pancreat cancer melanoma
compani mention note
peter lawson herebi certifi view express research report accur reflect
person view subject compani secur also certifi
receiv direct indirect compens exchang express specif
recommend report
